Business Context and Reporting Period
This Form 8-K Current Report was filed by Arvinas, Inc. on December 14, 2022, regarding corporate governance changes effective December 15, 2022. The company is a biotechnology firm incorporated in Delaware and listed on The Nasdaq Stock Market under the symbol ARVN.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Board Resignation: Bradley Margus resigned from the Board of Directors and the Audit Committee effective December 15, 2022. The resignation was not due to any disagreement regarding company operations or policies.
- Officer Appointment: David Loomis was appointed as Principal Accounting Officer, replacing Sean Cassidy in that specific role. Mr. Cassidy remains Chief Financial Officer and Treasurer.
- Director Election: Everett Cunningham was elected as a Class III Director and appointed to the Audit Committee to replace Mr. Margus.
Compensation and Management Commentary
David Loomis (Principal Accounting Officer)
- Base Salary: $375,000 annually.
- Bonus Target: 35% of base salary.
- Sign-on Bonus: One-time payment of $175,000 (subject to repayment agreement).
- Equity Grants:
- Options to purchase 27,500 shares at $41.39 per share (granted Dec 2, 2022).
- 2,750 Restricted Stock Units (RSUs) granted Dec 13, 2022.
- Vesting: Options vest 25% after 12 months and 75% over 36 months. RSUs vest 25% annually.
Everett Cunningham (Director)
- Cash Compensation: $40,000 annual director fee plus $10,000 for Audit Committee service.
- Equity Grant: Stock option with a grant date fair value of $750,000 to purchase shares at $37.15 per share.
- Vesting: Monthly vesting over three years.
- Indemnification: Standard indemnification agreement entered into for legal expenses and liabilities arising from director service.
Investor Verification Checklist
- Verify the continued tenure of Sean Cassidy as Chief Financial Officer despite the change in Principal Accounting Officer.
- Confirm the vesting schedules and exercise prices for the new equity grants issued to Mr. Loomis and Mr. Cunningham.
- Review the composition of the Audit Committee, now consisting of Linda Bain (Chair), Leslie Norwalk, and Everett Cunningham.
- Check for any subsequent filings regarding the repayment agreement tied to Mr. Loomis's sign-on bonus.